Objective: This study examined whether subcortical volumes of the basal gan
glia and thalamus in schizophrenic patients are related to neuroleptic expo
sure and symptom severity. Method: Basal ganglia substructures and thalamic
volumes were measured with magnetic resonance imaging in 96 patients with
schizophrenia (50 men and 46 women) and 128 healthy comparison subjects (60
men and 68 women). Twenty-one of the patients were neuroleptic-naive; of t
he 75 previously treated patients, 48 had received typical neuroleptics onl
y, and 27 had received typical and atypical neuroleptics. The relation of v
olume measures to treatment status, exposure to neuroleptics, and symptoms
was examined. Results: The neuroleptic-naive patients did not differ from t
he healthy comparison subjects in subcortical volumes except for lower thal
amic volume. In the neuroleptic-naive group, volumes did not correlate with
severity of negative symptoms, but higher volumes in both the thalamus and
the putamen were associated with more severe positive symptoms. The previo
usly treated group showed higher volumes in the putamen and globus pallidus
than the healthy comparison subjects and the neuroleptic-naive patients. i
n the treated group, a higher dose of a typical neuroleptic was associated
with higher caudate, putamen, and thalamus volumes, whereas a higher dose o
f an atypical neuroleptic was associated only with higher thalamic volume.
Higher subcortical Volumes were mildly associated with greater severity of
both negative and positive symptoms. Conclusions: Increased subcortical vol
umes in treated schizophrenic patients seem to be medication-induced hypert
rophy. This hypertrophy could reflect structural adaptation to receptor blo
ckade and may moderate the effects of neuroleptic treatment.